Tamsulosin 0.8 mg daily dose in management of BPH patients with failed tamsulosin 0.4 mg monotherapy and unfit for surgical intervention.
Mohamed Mahmoud DoghaHossam ShakerAssem AbdelazeezAhmed Abd-El LatifMahmoud S ElAdawyPublished in: World journal of urology (2024)
Double-dose 0.8mg tamsulosin as an alpha-blocker therapy appears to be a viable temporary management option for BPH patients who have not responded to the standard single dose 0.4mg tamsulosin and are not suitable candidates for TUR intervention.
Keyphrases
- benign prostatic hyperplasia
- lower urinary tract symptoms
- randomized controlled trial
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- peritoneal dialysis
- mesenchymal stem cells
- patient reported outcomes
- combination therapy
- angiotensin converting enzyme
- angiotensin ii